Upstream Bio Earnings Call Transcripts
Fiscal Year 2026
-
Verekitug demonstrated strong efficacy and quarterly dosing in phase II asthma trials, with plans to start phase III in severe asthma and CRSwNP by early next year. The COPD program is over 60% enrolled, and device development is progressing in parallel. Cash runway extends through 2027.
-
Verekitug demonstrated strong efficacy and safety in phase II trials for asthma and CRSwNP, with quarterly dosing matching or exceeding competitors. Phase III trials are planned for year-end, with advanced manufacturing and regulatory preparations supporting a rapid path to market.
-
VALIANT phase II results show verekitug significantly reduced asthma exacerbations and improved lung function and biomarkers at both 12- and 24-week dosing intervals, with a favorable safety profile. These findings support advancing to phase III trials in severe asthma and CRSwNP.
-
Verekitug, a TSLP receptor-targeting biologic, shows strong efficacy and safety in CRS with NP and is advancing in severe asthma and COPD. Upcoming phase II asthma data will guide phase III plans, with a focus on infrequent dosing and broad patient reach.
Fiscal Year 2025
-
Verekitug’s phase II data in CRS with NP demonstrated strong efficacy and extended dosing, supporting rapid advancement to phase III trials in both CRS and severe asthma. The molecule’s unique receptor targeting and durability set it apart from competitors.
-
VALIANT asthma study data is expected in Q1 2026, with robust efficacy benchmarks and a focus on extended dosing intervals. Plans include simultaneous Phase 3 trials for asthma and sinusitis, leveraging verekitug's high potency and broad patient eligibility.
-
Positive phase 2 results in CRSwNP and robust pharmacodynamic data support extended dosing intervals and differentiation from competitors. Phase 2 asthma data are expected in Q1, with phase 3 programs for both indications to follow after data review and regulatory input.
-
Verekitug, a potent TSLP receptor-targeting antibody, demonstrated robust efficacy and safety in phase II CRSwNP trials, with infrequent dosing and strong biomarker suppression. Upcoming severe asthma and COPD data may further support its differentiated profile and commercial potential.
-
Viraqita, a TSLP receptor antagonist, shows strong phase 2 efficacy in chronic rhinosinusitis with nasal polyps, matching or exceeding key competitors with less frequent dosing. Upcoming asthma data may further validate its unique pharmacology and broad potential.
-
Verekitug, dosed every 12 weeks, demonstrated significant efficacy and safety in phase II CRS with NP, reducing nasal polyp scores and the need for steroids or surgery, with a favorable safety profile and potential for less frequent dosing compared to other biologics.
-
Verekitug, a TSLP receptor-targeting antibody, shows promise for superior efficacy and extended dosing in severe asthma and CRS with NP, with phase 2 data expected soon. Market research highlights dosing convenience as a key differentiator, and the company is well-funded through 2027.
-
Verekitug, a TSLP receptor-targeting therapy, is advancing through Phase II trials in severe asthma and CRS with NP, with a COPD program in planning. The asset’s differentiated dosing and efficacy profile, strong IP, and robust cash position support a strategy focused on large, under-penetrated markets.
-
Virecetug, a TSLP receptor-targeting antibody, is advancing in phase 2 trials for severe asthma and nasal polyps, with a COPD program launching soon. Early data show strong efficacy and less frequent dosing potential, positioning it for significant market opportunity if confirmed.
-
Verecitug, a TSLP receptor-targeting antibody, is advancing through phase 2 trials for severe asthma and CRSwNP, with a COPD program launching soon. The drug's high potency enables infrequent dosing, and robust funding supports key milestones through 2028.
Fiscal Year 2024
-
Verekitug, a monoclonal antibody targeting the TSLP receptor, is advancing through robust phase 2 trials in severe asthma and chronic sinusitis with nasal polyps, with data expected in 2026 and later this year, respectively. Its unique mechanism enables extended dosing and may offer efficacy and convenience advantages in a growing biologics market.